Parenteral Formulation Development With Captisol®

Over the years, Singota Solutions has successfully executed numerous formulation development projects on behalf of its clients, many of which involved overcoming complex challenges related to solubility enhancement and drug stability optimization. These formulation hurdles are particularly common in the development of both small and large molecule therapeutics, where poor aqueous solubility or instability can severely limit the efficacy, bioavailability, and shelf life of a drug product.

In the course of addressing these challenges, Singota has consistently leveraged innovative technologies to deliver effective solutions. One such technology that has played a critical role in driving formulation success is Captisol®, developed by Ligand Pharmaceuticals. Captisol is a proprietary, patent-protected, and uniquely modified cyclodextrin designed to enhance the solubility, stability, and bioavailability of active pharmaceutical ingredients (APIs).

By incorporating Captisol into its formulation strategies, Singota has helped clients advance their drug candidates more efficiently and with greater confidence in product performance. As formulation demands continue to evolve, technologies like Captisol remain integral to developing high-quality, patient-friendly drug products that meet regulatory expectations and commercial goals.

Discover how Captisol’s uniquely engineered chemical structure enhances the solubility, stability, and bioavailability of both small molecule drugs and complex biologics, making it an indispensable tool in modern pharmaceutical development.